Around the world, more people are living sedentary lifestyles and consuming high-energy diets, augmenting the rate of Metabolic Syndrome (MetS) and its associated complications ([@B1]). With an estimated 20% -- 25% of the world\'s adult population positive for MetS, it is now one of the most prevalent chronic diseases ([@B2]). MetS has become a significant health concern, especially in some developing countries. According to a recent report, the MetS rate in Mexico is an alarming 54.8% and rising annually ([@B3]). Moreover, studies have shown that MetS is associated with a 5-fold risk of developing type-2 diabetes (T2D) and a 2-fold risk for cardiovascular disease ([@B4]).

Diagnosing MetS implies substantial costs, which in Mexico and other developing countries can be overwhelming for both the patient and the government health budget. The disorder is characterized by the presence of multiple risk factors: central obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low plasma high-density lipoprotein ([@B5], [@B6]). Measuring the last three components involves a blood sample drawn by a trained professional in a medical office, laboratory, or hospital; a blood pressure reading; and a follow-up appointment to discuss laboratory results. For the *Instituto Mexicano del Seguro Social* (Mexican Social Security Institute; IMSS), the cost of blood work to diagnose MetS is US\$ 37.45 (19.46 pesos/US\$) per patient; costs are higher at a private clinic ([@B7]). Moreover, since the average Mexican makes US\$ 292.50 per month ([@B8]), most opt not to receive preventive medical care.

Given the expenses and resources required to make a MetS diagnosis, large-scale screenings are impractical. However, there is plenty of evidence to support the use of alternative, non-laboratorial diagnosis since MetS is associated with multiple alternative factors. For example, a diet high in carbohydrates (\> 258 g daily) was shown to induce the glycemic index, which was positively associated with MetS development ([@B9]). Another factor was Acanthosis Nigricans, a dermatoses characterized by warty plaques with hyperkeratosis, papillomatosis, and hyperpigmentation, occurring mainly on the neck, armpits, and inguinal area ([@B10]). The presence of Acanthosis Nigricans on the neck has been shown to be a reliable clinical indicator of insulin resistance (IR), an important component of MetS ([@B11]). In addition, in males there is a strong association between MetS and erectile dysfunction ([@B12]); and in females, between MetS and maternal body mass index (BMI) and fetal macrosomia ([@B13]). Lastly, other anthropometric measurements, such as the waist-to-height ratio, have been correlated with MetS ([@B14]).

Due to the challenges of screening large populations, there is a new push to use simpler, less costly techniques, such as the self-reported questionnaire. The advantages of such a tool are that it is easy to administer, requires relatively little time, does not require a blood sample or specialized staff, and has lower costs associated with its application. Most self-reported questionnaires have been shown to have good predictive capacity; for example, the American Diabetes Association developed a questionnaire ([@B15], [@B16]) to determine risk for T2D, with satisfactory concordance (sensitivity = 79%; specificity = 65%). Use of a questionnaire for MetS diagnosis has recently been investigated. In Greece, the Finnish diabetes risk score (FINDRISC) questionnaire ([@B17]) was shown to predict MetS with high sensitivity (89% -- 98%), but poor specificity (14% -- 37%). Tan and colleagues ([@B18]) demonstrated that the Japanese Metabolic Syndrome Risk Score (JAMRISC) questionnaire was superior to FINDRISC (sensitivity = 100%; specificity 72%). Others have tried to develop a MetS risk questionnaire, but have failed to attain the quality of the JAMRISC ([@B19], [@B20]). The JAMRISC questionnaire, however, has questions not applicable in Latin America, such as consumption of sake.

Given the usefulness of questionnaires for MetS diagnosis, the high prevalence of MetS in Mexico, and the high cost of its diagnosis in the country, there was clearly a need for a Mexican MetS instrument. This study sought to evaluate the reliability of the newly developed *Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I* (ESF-I)---a questionnaire based on alternative, non-laboratorial parameters associated with an increased risk of developing MetS---for determining the presence of MetS among the population of central Mexico.

MATERIALS AND METHODS
=====================

Study design and participants
-----------------------------

This was a cross-sectional study of males and non-pregnant females ≥ 18 years of age, recruited in June 2012 -- August 2013, from the City of Puebla, State of Puebla, an urban area in Mexico\'s central region. The participants were attending the IMSS Family Medicine Clinic \#2 and had come in for either a normal check-up (well visit) or were accompanying a family member, who was also eligible to attend the clinic. Due to IMSS policies, a possible 135 000 individuals can attend this clinic. For this study, individuals with or without diabetes could be included; those excluded had an incomplete clinical history or were suspected of having hypo- or hyperthyroidism, pituitary adenoma, rheumatoid arthritis, lupus, or any acute or chronic illness that would interfere with the analysis.

Clinical characterization
-------------------------

Participants were clinically evaluated according to a standardized protocol that included personal and family history. With the subjects in light clothing and without shoes, height and weight were determined using the Tanita Body Composition Analyzer (Model TBF-215, Tanita, Tokyo, Japan). BMI was calculated as weight/height^2^ (kg/m^2^). Subjects were classified according to established criterion ([@B21]) as normal weight (BMI: \< 24.9 kg/m^2^), overweight (BMI: 25 -- 29.9 kg/m^2^), or obese (BMI \> 30 kg/m^2^). After resting for at least 5 minutes and in a seated position, each patient\'s blood pressure was taken on the right arm with a mercury-column sphygmomanometer or an electric blood pressure monitor with an appropriately sized cuff. The data are the average of two physician-obtained measurements.

Biochemical assays
------------------

Following a 10 -- 12 hr overnight fast, whole blood samples were collected from the antecubital vein into a BD Vacutainer^®^ K2 (Becton, Dickinson & Co., Franklin Lakes, New Jersey, United States) containing ethylenediaminetetraacetic acid or BD Vacutainer^®^ Serum separator tubes with separator gel. The samples were kept at room temperature to allow clotting. The serum fraction was recovered and frozen at −20 °C until use. Samples were used for the following endpoints: fasting plasma glucose, insulin, glycated hemoglobin (HbA1c), total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. An additional blood sample was obtained 2 hours after oral glucose administration (75 g) to determine tolerance. Fasting plasma glucose and oral glucose tolerance were determined, in duplicate, using the enzymatic method/spectrophotometric glucose oxidation (Beckman Coulter Inc., Brea, California, United States). The HbA1c levels were determined by the turbidimetric inhibition immunoassay. Insulin levels were determined by an automated immunoassay (Beckman Coulter Inc.). To determine total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides, serum samples were sent to the Central Laboratory of the Multidisciplinary Research Group, which is part of IMSS.

MetS definitions
----------------

To classify subjects as normal (MetS--) or having Metabolic Syndrome (MetS+), three definitions were used. The Harmonized definition ([@B22]) requires three of the following five criteria: (i) waist circumference: ≥ 90 cm for men and ≥ 80 cm for women; (ii) triglycerides: ≥ 150 mg/dL or drug treatment for elevated triglycerides; (iii) high-density lipoprotein: \<40 mg/dL for men and \< 50 mg/dL for women or drug treatment for high-density lipoprotein levels; (iv) hypertension: systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or antihypertensive drug treatment; or (v) impaired glucose tolerance: fasting plasma glucose ≥ 100 mg/dL or drug treatment for elevated glucose. The National Cholesterol Education Program Adult Treatment Panel III (ATPIII) definition ([@B23]) requires three of the following five criteria: (i) waist circumference: ≥ 102 cm for men or ≥ 88 cm for women; (ii) triglycerides: ≥ 150 mg/dL; (iii) high-density lipoprotein: \< 40 mg/dL for men and \< 50 mg/dL for women; (iv) hypertension: systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg; or (v) impaired glucose tolerance: fasting plasma glucose ≥ 110 mg/dL or diabetes. The International Diabetes Federation (IDF) definition ([@B24]) requires central adiposity (waist circumference: ≥ 90 cm for men, ≥ 80 cm for women, or BMI \> 30 kg/m^2^) and two of the following four criteria: (i) triglycerides ≥ 150 mg/dL or using triglycerides lowering medication; (ii) high-density lipoprotein: \< 40 mg/dL for men, \< 50 mg/dL for women, or using high-density lipoprotein augmenting medication; (iii) hypertension: systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg, or treatment for hypertension; or (iv) impaired glucose tolerance: fasting plasma glucose ≥ 100 mg/dL or diagnosed with diabetes.

Study instrument
----------------

The ESF-I questionnaire was designed with 15 questions/criteria to assess key non-laboratorial measures that were associated with increased risk or prevalence of MetS. The study instrument is available upon request from the corresponding author. This questionnaire focused on anthropometric measurements and alternative clinical data, including erectile dysfunction, history of macrosomia, postprandial somnolence, Acanthosis Nigricans, hypertension, age, family history of T2D, blurry vision, polydipsia, polyuria, polyphagia, and dietary intake. Some questions were developed after searching for key factors associated with insulin resistance and MetS, whereas others were developed based on the knowledge and experience of a five-person panel. Some questions contained sex-specific cutoff-values for people in central Mexico. The final question was sex based, where a positive result for any of the sub-questions was considered a positive result for the whole question. Each positive response was given 1 point and summed to obtain a total value out of a maximum score of 15.

One of two doctors applied the questionnaire, reading the questions for the participant and taking measurements of the waist, hip, and height. When, a subject did not understand the question, this was noted, and depending on the question, the doctor gave a standard response. Worth noting is that the questions that provoked the most concern were those on consumption ≥ 300 grams of carbohydrates and Acantosis Nigricans. The total time required ranged from 10 -- 15 minutes. Participants were then scheduled for a fasting blood-draw within 1 -- 2 weeks.

Statistical analysis
--------------------

Statistical analyses were performed using the IBM SPSS Statistics software, version 21 (SPSS Inc., an IBM company, Chicago, Illinois, United States). Normality of continuous variables was determined using Kolmogorov-Smirnov test. Levene\'s test was used to examine difference in the variances of continuous variables. Associations were determined by calculating Spearman coefficient rho (ρ) ([@B25]). Cohen´s kappa (κ) was calculated to determine inter-assay agreement. Receiver-operating characteristic curve analysis was used to determine specificity and sensitivity between the ESF-I questionnaire and MetS. The area under the receiver-operating characteristic curve (AUC) was calculated using the method described by Hanley and McNeil ([@B26]). Using the sensitivity and specificity, the Youden\'s index (sensitivity + specificity -- 1) was calculated and the highest score was considered the optimal cutoff value. Logistic regression was used to determine association (Odds Ratio \[OR\] and 95% confidence intervals \[95%CI\]) between the ESF-I questionnaire and MetS. Internal consistency was measured by Cronbach\'s α (α = 0.766). A post-hoc analysis was performed to determine if an acceptable power had been achieved. Using the MedCalc^®^ Version 13.3.3.0 software (Medcalc, Ostend, Belgium), the sample size of 72 was determined using AUC of 0.80 with a positive to negative ratio of 1, assuming an alpha and beta of 0.01. *P* values \< 0.05 (two-tailed) were considered statistically significant. Results are expressed as the mean ± standard deviation.

**Ethics.** All participants provided written, informed consent, in accordance with the Declaration of Helsinki. To ensure the participant\'s confidentiality, the participant\'s IMSS identification number was used for any labs. Afterwards, the identification number was recoded to a Protocol Association number. The study protocol was approved by the Scientific Research and Ethics Committees of IMSS (IMSS Committee: Registry number: R-2014-2102-1).

RESULTS
=======

Participants' characteristics
-----------------------------

Initially, 242 participants from 19 -- 77 years of age were approached for this study (96 males and 136 non-pregnant females); however, 10 were excluded for incomplete laboratory reports. Thus, the study cohort consisted of 232 subjects, of which 26.3% were positive for T2D ([Table 1](#t1){ref-type="table"}); 5 (0.46%) were morbidly obese; 50.4% had attended or graduated from a university; 15.0% had completed a high school education; 9.4% had completed secondary (middle) school, whereas 25.2% had attained only a primary school education.

###### Characteristics of study participants from the Mexican Social Security Institute Family Medicine Clinic \#2, according to three definitions of Metabolic Syndrome: the Harmonized, the National Cholesterol Education Program Adult Treatment Panel III (ATPIII), and the International Diabetes Federation (IDF) definitions; Puebla, Mexico, June 2012 -- August 2013

  Category                                 Harmonized[a](#TFN1){ref-type="table-fn"}   ATPIII[a](#TFN1){ref-type="table-fn"}           IDF[a](#TFN1){ref-type="table-fn"}                                                                                                                                                               
  ---------------------------------------- ------------------------------------------- ----------------------------------------------- ------------------------------------------------ ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ------------------------------------------------
  Sample (male / female)                   107 (43/64)                                 125 (53/72)                                     91 (38/53)                                       141 (58/83)                                     102 (45/57)                                     130 (51/79)                                     
  Age (years)                              40.30 ± 14.00                               47.86 ± 12.91[b](#TFN2){ref-type="table-fn"}    40.03 ± 14.47                                    47.17 ± 12.84[b](#TFN2){ref-type="table-fn"}    40.95 ± 14.75                                   47.05 ± 12.65^\*^                               
  Height (m)                               160.41 ± 8.68                               159.74 ±10.30                                   160.99 ± 8.66                                    159.44 ± 10.10                                  160.81 ± 8.65                                   159.45 ± 10.23                                  
  Weight (kg)                              62.77 ± 11.47                               77.08 ± 15.98[b](#TFN2){ref-type="table-fn"}    61.59 ± 10.86                                    76.21 ± 15.81[b](#TFN2){ref-type="table-fn"}    61.11 ± 10.50                                   77.57 ± 15.61[b](#TFN2){ref-type="table-fn"}    
  Waist circumference (cm)                 85.07 ± 10.76                               100.18 ± 12.09[b](#TFN2){ref-type="table-fn"}   83.60 ± 10.20                                    99.41 ± 12.06[b](#TFN2){ref-type="table-fn"}    83.52 ± 9.78                                    100.82 ± 11.41[b](#TFN2){ref-type="table-fn"}   
  Body Mass Index (kg/m^2^)                24.37 ± 3.88                                30.17 ± 5.44[b](#TFN2){ref-type="table-fn"}     23.73 ± 3.47                                     29.93 ± 5.34[b](#TFN2){ref-type="table-fn"}     23.72 ± 3.30                                    30.46 ± 5.22[b](#TFN2){ref-type="table-fn"}     
                                           Normal weight (%)                           59.80                                           18.40[b](#TFN2){ref-type="table-fn"}             67.00                                           18.40[b](#TFN2){ref-type="table-fn"}            69.60                                           12.30[b](#TFN2){ref-type="table-fn"}
                                           Overweight (%)                              31.80                                           40.00                                            26.400                                          42.60[b](#TFN2){ref-type="table-fn"}            24.50                                           45.40[b](#TFN2){ref-type="table-fn"}
                                           Obese (%)                                   8.40                                            41.60[b](#TFN2){ref-type="table-fn"}             6.60                                            39.00[b](#TFN2){ref-type="table-fn"}            5.90                                            42.40[b](#TFN2){ref-type="table-fn"}
  Systolic blood pressure (mmHg)           112.15 ± 9.69                               120.78 ± 12.94[b](#TFN2){ref-type="table-fn"}   112.53 ± 10.03                                   119.55 ± 12.87[b](#TFN2){ref-type="table-fn"}   113.07 ± 10.04                                  119.67 ± 13.13[b](#TFN2){ref-type="table-fn"}   
  Diastolic blood pressure (mmHg)          71.87 ± 9.35                                77.46 ± 9.84[b](#TFN2){ref-type="table-fn"}     72.64 ± 9.32                                     76.32 ± 10.18[b](#TFN2){ref-type="table-fn"}    73.07 ± 9.27                                    76.27 ± 10.34[b](#TFN2){ref-type="table-fn"}    
  Fasting plasma glucose (mg/dL)           95.30 ± 11.14                               124.16 ± 48.03[b](#TFN2){ref-type="table-fn"}   93.75 ± 11.36                                    121.88 ± 45.66[b](#TFN2){ref-type="table-fn"}   97.75 ± 22.01                                   121.13 ± 45.50[b](#TFN2){ref-type="table-fn"}   
  Post-prandial glucose (mg/dL)            106.98 ± 32.11                              147.01 ± 48.57[b](#TFN2){ref-type="table-fn"}   104.72 ± 32.59                                   142.90 ± 46.84[b](#TFN2){ref-type="table-fn"}   105.63 ± 33.07                                  144.47 ± 46.99[b](#TFN2){ref-type="table-fn"}   
  HbA1c (mmol/mol)                         4.96 ± 1.24                                 6.00 ± 1.74[b](#TFN2){ref-type="table-fn"}      4.97 ± 1.31                                      5.88 ± 1.70[b](#TFN2){ref-type="table-fn"}      5.15 ± 1.53                                     5.82 ± 1.62[b](#TFN2){ref-type="table-fn"}      
  Fasting plasma insulin (μU/dL)           8.41 ± 6.09                                 13.65 ± 8.00[b](#TFN2){ref-type="table-fn"}     8.03 ± 6.26                                      13.30 ± 7.74[b](#TFN2){ref-type="table-fn"}     8.11 ± 6.24                                     13.69 ± 7.74[b](#TFN2){ref-type="table-fn"}     
  American Diabetes Association criteria                                                                                                                                                                                                                                                                                                
                                           Normal glucose tolerance (%)                60.70                                           16.80[b](#TFN2){ref-type="table-fn"}             71.40                                           14.90[b](#TFN2){ref-type="table-fn"}            65.70                                           14.60[b](#TFN2){ref-type="table-fn"}
                                           Pre-diabetics (%)                           32.70                                           40.00                                            22.00                                           46.10[b](#TFN2){ref-type="table-fn"}            23.50                                           46.90[b](#TFN2){ref-type="table-fn"}
                                           Type 2 diabetics (%)                        6.50                                            43.20[b](#TFN2){ref-type="table-fn"}             6.60                                            39.00[b](#TFN2){ref-type="table-fn"}            10.80                                           38.50[b](#TFN2){ref-type="table-fn"}
                                           Total cholesterol (mg/dL)                   156.11 ± 54.87                                  168.64 ± 50.85                                   157.10 ± 54.07                                  166.58 ± 52.15                                  158.00 ± 53.06                                  166.68 ± 52.84
                                           High Density Lipoprotein (mg/dL)            47.98 ± 11.69                                   35.26 ± 10.62[b](#TFN2){ref-type="table-fn"}     49.42 ± 11.84                                   35.78 ± 10.31[b](#TFN2){ref-type="table-fn"}    47.30 ± 12.93                                   36.28 ± 10.40[b](#TFN2){ref-type="table-fn"}
                                           Low-Density Lipoprotein (mg/dL)             112.07 ± 32.86                                  130.86 ± 105.88                                  111.67 ± 32.58                                  129.01 ± 100.49                                 111.62 ± 33.40                                  130.75 ± 104.42
                                           Triglycerides (mg/dL)                       125.33 ± 69.27                                  224.84 ± 133.25[b](#TFN2){ref-type="table-fn"}   151.10 ± 54.07                                  166.58 ± 52.15[b](#TFN2){ref-type="table-fn"}   136.60 ± 85.61                                  212.17 ± 131.02[b](#TFN2){ref-type="table-fn"}
  Questionnaire                            4.28 ± 2.35                                 8.27 ± 3.10[b](#TFN2){ref-type="table-fn"}      4.11 ± 2.30                                      7.93 ± 3.17[b](#TFN2){ref-type="table-fn"}      4.23 ± 2.40                                     8.16 ± 3.08[b](#TFN2){ref-type="table-fn"}      

Differences between normal subjects (MetS-) and subjects with MetS (MetS+) were determined by either Student\'s T-test or Chi^2^-test. Values are mean ± standard deviation or frequency.

*P*-values \< 0.05 (two-tailed) were considered significant.

Source

: Prepared by the authors from the study results.

It is worth noting that most definitions of MetS do not require the presence of T2D to confirm it. Depending on which of the three definitions of MetS was used, the portion of T2D subjects negative for MetS ranged from 11% -- 22%. The Harmonizing definition and the ATPIII definition had 93.1% agreement (κ = 0.860, *P* \< 0.001), whereas the Harmonizing and IDF had only 90.8% agreement (κ = 0.800, *P* \< 0.001). Interestingly, the IDF and the ATPIII had 95.2% agreement (κ = 0.903, *P* \< 0.001). Using the three different MetS definitions, from 53.8% -- 60.8% of the cohort was positive for MetS. As expected, the MetS+ group\'s age was significantly higher for the Harmonizing, ATPIII, and IDF definitions (*P* \< 0.001). For the five criteria of MetS, each was significantly higher, independent of the MetS definitions used (*P* \< 0.001). The anthropometric and biochemical characteristics are shown in [Table 1](#t1){ref-type="table"}. The average ESF-I questionnaire score was significantly higher in the MetS+ group for each definition (Harmonizing: 8.27 ± 3.10 versus 4.28 ± 2.35; ATPIII: 7.93 ± 3.17 versus 4.11 ± 2.30; and IDF: 8.16 ± 3.08 versus 4.23 ± 2.4; *P* \< 0.001).

ESF-I correlates with MetS and its components
---------------------------------------------

For the components of MetS, there was a moderate positive correlation between the ESF-I questionnaire and waist circumference (ρ = 0.611, *P* \< 0.001, [Figure 1](#f1){ref-type="fig"}) and a weak positive correlation for systolic blood pressure (ρ *=* 0.268, *P* \< 0.001), diastolic blood pressure (ρ = 0.149, *P* = 0.021), triglycerides (ρ = 0.301, *P* \< 0.001), and fasting plasma glucose (ρ = 0.319, *P* \< 0.001). There was a weak negative correlation between the ESF-I questionnaire and high-density lipoprotein (ρ = −0.278, *P* \< 0.001). Interestingly, there was a moderate positive correlation between the ESF-I questionnaire and MetS (Harmonizing definition: ρ = 0.591, ATPIII definition: ρ = 0.555, and IDF definition: ρ = 0.580, *P* \< 0.001).

![Association between the *Encuesta de Identificatión de Sujetos Metabólicamente Comprometidos en fase-I* (ESF-I) questionnaire and components of Metabolic Syndrome: systolic blood pressure (A), diastolic blood pressure (B), waist circumference (C), high-density lipoprotein (D), triglyceries (E), and fasting plasma glucose (F) (lines corresponds to linear fit with 95% Confidence Intervals). Puebla, Mexico, June 2012--August 2013.](rpsp-43-e9-g001){#f1}

Receiver-operating characteristic curve analysis was used to compare the effectiveness of the ESF-I questionnaire for determining MetS ([Figure 2](#f2){ref-type="fig"}). For the Harmonized definition, the AUC was 0.841 (95%CI: 0.790 -- 0.892, *P* \< 0.001) and analysis of the curve resulted in a suggested cutoff value of 7 (Youden index = 0.560, sensitivity = 72.8%, and specificity = 83.2%). For the ATPIII definition, the AUC was 0.827 (95%CI: 0.744 -- 0.880, *P* \< 0.001) and also a cutoff value of 7 was determined (Youden index = 0.520, sensitivity = 67.4%, and specificity = 84.6%). For the IDF definition, the AUC was 0.836 (95%CI: 0.785 -- 0.887, *P* \< 0.001) and a suggested cutoff value of 7 (Youden index = 0.520, sensitivity = 69.2%, and specificity = 81.4%).

![The diagnostic capability of the *Encuesta de Identificatión de Sujetos Metabólicamente Comprometidos en Fase-I* (ESF-I) questionnaire to determine Metabolic Syndrome (MetS). ROC curves were constructed and the AUCs were calculated for the EFS-I questionnaire to determine MetS, using the Harmonizing (black), the National Cholesterol Education Program Adult Treatment Panel III (ATPIII, dark gray), and International Diabetes Federation (IDF, light gray) definitions. Puebla, Mexico, June 2012 -- August 2013.](rpsp-43-e9-g002){#f2}

ESF-I score indicates increased risk for MetS
---------------------------------------------

Since the proposed cutoff value of 7 was determined for each MetS definition, the cohort was re-categorized. There was strong agreement between the ESF-I questionnaire and MetS, independent of the definition used (Harmonizing definition: test accuracy = 77.6%, positive prediction value (PPV) = 83.5%, negative prediction value (NPV) = 72.4%, κ = 0.554; ATPIII definition: test accuracy = 74.1%, PPV = 87.2%, NPV = 62.6%, κ = 0.489; and IDF definition: test accuracy = 74.6%, PPV = 82.6%, NPV = 67.5%, κ = 0.495, *P* \< 0.001). For the Harmonizing definition, the ESF-I questionnaire was strongly predictive of MetS (OR = 13.2, 95%CI: 7.0 -- 25.1, *P* \< 0.001, [Table 2](#t2){ref-type="table"}), with similar results for the ATPIII definition (OR = 11.3, 95%CI: 5.8 -- 22.2, *P* \< 0.001) and for the IDF definition (OR = 9.8, 95%CI: 5.27 -- 18.3, *P* = \< 0.001). There was no difference when adjusting for gender (Model 1) or gender and age (Model 2).

###### The association between the ESF-I questionnaire and Metabolic Syndrome, using a cutoff value of 7, for participants from the Mexican Social Security Institute Family Medicine Clinic \#2, Puebla, Mexico, June 2012 -- August 2013

  Criteria[a](#TFN3){ref-type="table-fn"}   Crude[b](#TFN4){ref-type="table-fn"}   Model 1[c](#TFN5){ref-type="table-fn"}   Model 2[d](#TFN6){ref-type="table-fn"}                                                        
  ----------------------------------------- -------------------------------------- ---------------------------------------- ---------------------------------------- ------ ------------- ---------- ------ ------------- ----------
  Harmonizing                               13.2                                   7.0 -- 25.1                              \< 0.001                                 13.4   7.1 -- 25.7   \< 0.001   11.8   6.0 -- 23.1   \< 0.001
  ATPIII[e](#TFN7){ref-type="table-fn"}     11.3                                   5.8 -- 22.2                              \< 0.001                                 11.4   5.8 -- 22.2   \< 0.001   10.0   4.5 -- 20.2   \< 0.001
  IDF[f](#TFN8){ref-type="table-fn"}        9.8                                    5.27 -- 18.3                             \< 0.001                                 9.8    5.2 -- 18.2   \< 0.001   9.1    4.7 -- 17.7   \< 0.001

OR = odds ratio; 95%CI = 95% confidence intervals.

OR and 95%CI were calculated using logistic regression.

Model 1 -- ORs were adjusted by gender.

Model 2 -- ORs were adjusted by gender and age.

ATPIII = the National Cholesterol Education Program Adult Treatment Panel III.

IDF = International Diabetes Federation.

Source

: Prepared by the authors from the study results.

DISCUSSION
==========

MetS represents a significant risk marker for the development of T2D and cardiovascular disease. However, there is an overwhelming economical, medical, and social imperative for the early identification of individuals with MetS. Early identification allows lifestyle interventions and treatments, which many reports have shown to prevent the development of T2D and cardiovascular disease ([@B27], [@B28]). Taking into consideration the cost of diagnosing the components of MetS, this study demonstrates that using the ESF-I questionnaire, based on alternative signs of MetS, can specifically identify MetS-positive individuals.

Currently, IMSS spends 30% of its non-labor budget treating complications in 15% of patients suffering from T2D, heart disease, kidney failure, and other noncommunicable and degenerative diseases, such as MetS ([@B29]). As postulated by Gonzalez Anaya and Garcia Cuellar, by using early detection strategies and increased patient adherence, as well as implementing improved preventive efforts, many of these complications could be mitigated ([@B29]). Thus, a new strategy for prevention was designed to aid in early detection. Here, we have demonstrated that the ESF-I questionnaire was specific for MetS detection. The PPV suggests that the questionnaire can identify these individuals, which could improve treatment outcomes for patients with newly identified MetS.

The cost associated with MetS diagnosis makes large-scale screening prohibitive. But with a questionnaire such as this one, there is no need to analyze blood samples or use specialized staff. In addition, with this questionnaire high-risk individuals can be identified during a consultation or by an alternate route, such as a website, mobile app, email, and postal mail (still widely used in rural areas of Mexico). However, the ability to implement the questionnaire without the aid of trained staff is a concern. Here, most of the participants had a high school education, but in rural areas that cannot be expected. Moreover, most patients were unfamiliar with Acanthosis Nigricans, which suggests that photos should be added to the questionnaire for clarification. Nonetheless, this questionnaire could be used to identify apparently healthy individuals that are at a higher risk of developing cardiovascular disease, T2D, or other metabolic comorbidities. This could reduce the number of consultations required for truly healthy individuals; reduce the expense in the number of consultations due to unnecessary laboratory work and appointments; and save time and money by providing earlier detection. However, when MetS is suspected, this questionnaire is not a replacement for doctor consultations or future medical appointments. Its sole purpose is to identify possible positive individuals.

Regarding the structure of the questionnaire, each question was based on the fact that each category was associated with an increased risk of MetS: family history of T2D (OR = 1.44); advanced age (OR = 1.81); obesity (OR = 2.62) ([@B30]); waist-to-height ratio (OR = 1.13); and waist circumference (OR = 1.95) ([@B14]). We also evaluated symptoms associated with the components of MetS, such as Acanthosis Nigricans ([@B11]), as an indicator of insulin resistance (OR = 3.35); erectile dysfunction ([@B12]), associated with elevated triglyceride levels (OR = 1.98); and a history of fetal macrosomia ([@B31]), associated with obesity and gestational diabetes (OR = 2.56). Even though the odds ratios for each category were different, each question was assigned a value of 1. The sensitivity and specificity of the ESF-I questionnaire could be increased by adjusting the point values. Moreover, we did not consider any biological interactions, which could affect the point distributions. Therefore, current studies are underway to determine any biological interactions or clustering to improve the accuracy of the ESF-I questionnaire.

In Mexico, the population\'s ethnic diversity includes Native American, European, and African, and can differ by geographic area. Unlike other parts of the world where European colonialism resulted in a significant decline in the native population, about 10% of the population of Mexico is indigenous; therefore, the majority of Mexicans are mestizos ([@B32]). Moreover, Moreno-Estrada and colleagues demonstrated that ethnic variation can affect disease development and prevalence ([@B33]). In the State of Puebla, the study population was a mix of indigenous and European ([@B32]); that being said, it represents the ethnicity of central Mexico. Therefore, since this questionnaire was only applied to central Mexicans and due to the great ethnic variations, we speculate that the results are specific to this geographic area.

This questionnaire is currently being tested in other areas of Mexico; however, ethnic-specific modifications are probably needed for successful application outside of Puebla, and especially in other countries of Latin America. With respect to non-Latin American countries, it remains unlikely that the ESF-I questionnaire could be utilized. As seen with the Japanese subjects, the JAMRISC questionnaire yielded superior identification for MetS than did the FINDRISC ([@B18]). However, future studies are required to modify questions with region-specific cutoff values.

**Limitations.** This study has a few limitations. First, principle component analysis was not performed to group the questions into categories. This could affect the distribution of points. However, this initial study determined that with the crude result, the ESF-I questionnaire was specific and sensitive for determining MetS. Second, the differences between female and male criteria could influence the result; however, we used gender-specific criteria to minimalize any gender bias. Third, as mentioned above, there are many non-laboratorial signs and symptoms that could have been used. We selected ones based on risk levels, reviews of the literature, and personal experiences. However, including more questions could improve the questionnaire\'s specificity and sensitivity; this idea is currently being investigated.

Conclusions
-----------

The ESF-I questionnaire was able to identify individuals with MetS with exceptional sensitivity among the population of central Mexico. This questionnaire can lead to earlier diagnoses, reduce the number of consultations, and lower costs with easier application.
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